CHMG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CHMG looks like a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The case is supported by strong Q1 financial growth, a higher analyst price target, and a constructive moving-average trend. While there is no strong proprietary buy signal today and momentum is a bit stretched, the overall setup is still favorable for a long-term entry at the current price.
CHMG is trading in an uptrend, with bullish moving averages in place (SMA_5 > SMA_20 > SMA_200), which supports positive trend structure. The MACD histogram is slightly negative and contracting, suggesting near-term momentum has cooled a bit, but not enough to damage the broader trend. RSI_6 at 75.855 indicates the stock is running hot and near overbought territory, so short-term upside may be less immediate. Price is close to resistance at R1 69.257, with pivot support at 67.347 and deeper support at 65.437. Overall, the trend remains bullish, but the current price is closer to resistance than support.
Q1 2026 financial results were strong, with revenue up 15.80% YoY, net income up 54.53% YoY, and EPS up 51.59% YoY. Keefe Bruyette raised its price target to $72 from $64 and described the Q1 report as impressive, with outlook stable and strong growth. The stock is also showing a positive price trend through its moving averages.
No recent news in the last week, so there is no fresh event-driven catalyst. Hedge funds and insiders are neutral, with no significant trading trends over the last quarter or month. The MACD histogram is still below zero, RSI is elevated, and similar candlestick patterns suggest a possible near-term pullback or muted returns over the next day, week, and month.
In Q1 2026, Chemung Financial posted solid growth across the board. Revenue increased to 28,822,000, up 15.80% year over year. Net income rose to 9,199,000, up 54.53% year over year, and EPS increased to 1.91, up 51.59% year over year. This is a strong latest-quarter performance and shows improving profitability and earnings leverage.
Recent analyst action is positive but still cautious. On 2026-04-20, Keefe Bruyette raised the price target to $72 from $64 and kept a Market Perform rating. The firm called Q1 'impressive' and said the outlook is stable with strong growth and some normalization in fees/expenses. Wall Street’s view is balanced: the pros see improving fundamentals and a higher fair value, while the neutral rating suggests limited upside conviction compared with a full Buy.
